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Composite regulation of ERK activity dynamics
underlying tumour-speciﬁc traits in the intestine
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Hiroshi Seno2, Kazuhiro Aoki8,9, Michiyuki Matsuda1,5 & Masamichi Imajo5
Acting downstream of many growth factors, extracellular signal-regulated kinase (ERK) plays
a pivotal role in regulating cell proliferation and tumorigenesis, where its spatiotemporal
dynamics, as well as its strength, determine cellular responses. Here, we uncover the ERK
activity dynamics in intestinal epithelial cells (IECs) and their association with tumour
characteristics. Intravital imaging identiﬁes two distinct modes of ERK activity, sustained and
pulse-like activity, in IECs. The sustained and pulse-like activities depend on ErbB2 and EGFR,
respectively. Notably, activation of Wnt signalling, the earliest event in intestinal tumor-
igenesis, augments EGFR signalling and increases the frequency of ERK activity pulses
through controlling the expression of EGFR and its regulators, rendering IECs sensitive to
EGFR inhibition. Furthermore, the increased pulse frequency is correlated with increased cell
proliferation. Thus, ERK activity dynamics are deﬁned by composite inputs from EGFR and
ErbB2 signalling in IECs and their alterations might underlie tumour-speciﬁc sensitivity to
pharmacological EGFR inhibition.
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The extracellular signal-regulated kinase (ERK) signallingpathway regulates a variety of biological processesincluding cell proliferation, survival, differentiation, and
tumorigenesis1, 2. Since ERK activation promotes proliferation of
many types of cells, its deregulated/constitutive activation is often
observed in various cancers. Among many growth factor recep-
tors, epidermal growth factor receptor (EGFR) plays a pivotal role
in activating ERK in normal and cancerous epithelia3, therefore,
EGFR–ERK signalling has been of particular interest in cancer
biology4, 5. In the classical view, EGF stimulation simply triggers
transient and short-lived ERK activation1, 6. However, recent
studies using a highly sensitive biosensor for ERK activity7 have
revealed that EGF signalling can generate complex spatio-
temporal ERK activity at the single cell level8–10. For instance,
certain types of cultured cells show considerable heterogeneity in
ERK activity due to spontaneous ERK activation pulses and its
lateral propagation to adjacent cells, both of which were asso-
ciated with cell proliferation8, 10. Similarly, propagation of ERK
activity and its correlation with cell proliferation were also
observed in the mouse skin11. Notably ERK activity dynamics as
well as its overall strength can be a critical determinant of cell
proliferation8, 9. Moreover, difference in ERK activity dynamics
leads to different outputs in some biological processes. For
example, in PC12 cells, treatment with NGF or FGF induces
prolonged ERK activation and neuronal differentiation12, 13,
whereas EGF treatment generates only transient, pulse-like ERK
activation without inducing the differentiation13. Despite its
obvious importance, however, how ERK activity dynamics
are regulated and how they affect the physiological processes
remains unknown.
The intestinal epithelium is one of the representative tissues in
which EGFR–ERK signalling regulates both normal homoeostasis
and tumorigenesis14. In this tissue, actively dividing stem cells
expressing a marker gene, LGR5, support the rapid and constant
renewal of the entire epithelium15. In mice, depletion of either
EGFR or three of its ligands, EGF, amphiregulin, and TGF-α,
impairs proliferation of intestinal stem cells (ISCs) and progenitor
cells16, 17. Conversely, excessive activation of EGFR signalling by
depleting its negative regulator, Lrig1, induces ISC expansion and
tumour development18, 19. In line with these ﬁndings, EGFR sig-
nalling has also been implicated in human colorectal cancer
(CRC). Typically, sporadic CRCs develop through the
adenoma–carcinoma sequence, an archetypal model of multi-step
carcinogenesis20. In this model, mutations in the adenomatous
polyposis coli (APC) gene have been regarded as the earliest and
the rate-limiting events of tumour initiation. Following APC
mutations, sequential accumulation of other genetic mutations
including KRAS, BRAF, PIK3CA, SMAD4, and TP53 mutations
transforms the tissue to malignant tumours20–22. In addition,
EGFR overexpression is also observed in human CRCs, and is
associated with poor prognosis23–26. Pharmacological inhibition of
EGFR signalling has been shown to be effective against these
cancers27. However, mutations in KRAS or BRAF desensitize
CRCs to EGFR inhibition28, suggesting that RAS-RAF-ERK sig-
nalling mediates the tumour-promoting activity of EGFR signal-
ling. Collectively, these reports suggest that EGFR–ERK signalling
is a key driver of stem/progenitor cell proliferation and tumour
progression in the intestinal epithelium in both mice and humans.
However, EGFR–ERK signalling dynamics and their regulatory
mechanisms remain unknown due to technical difﬁculties.
Recent advances in detecting ERK activity using ﬂuorescent
biosensors and culturing primary intestinal epithelial cells (IECs)
as organoids29 have paved the way to visualize EGFR–ERK sig-
nalling dynamics in this tissue. Since intestinal organoids com-
prise IECs without any genetic mutations and can be cultured in
serum-free media, dynamic regulation of the EGFR–ERK
pathway and its interaction with other pathways can be readily
analyzed. Here, by taking the full advantage of the organoid
culture method and a highly sensitive biosensor for ERK activity,
we uncover the ERK activity dynamics in IECs. We demonstrate
the presence of two distinct modes of ERK activity, sustained,
constant activity and pulse-like activity, both in vivo and in vitro.
Our analyses show that the two modes of ERK activity are gen-
erated by different EGFR family receptors. Moreover, we reveal
that Wnt signalling activation alters the ERK signalling dynamics,
which underlies the enhanced responsiveness of tumour cells to
EGFR inhibition.
Results
In vivo imaging of ERK activity in the mouse small intestine.
To reveal the ERK activity dynamics in the intestinal epithelium,
we used transgenic mice ubiquitously expressing a highly sensi-
tive Förster resonance energy transfer (FRET) biosensor for ERK
activity (EKAREV-NLS) (Fig. 1a)30. The small intestine of
EKAREV-NLS mice was observed under an inverted two-photon
excitation microscope (Fig. 1b). By this approach, ERK activity
represented by the FRET/CFP ratio could be live-imaged at a
single-cell resolution in areas ranging from the crypt bottom to
the villus (Supplementary Fig. 1a). To validate the speciﬁcity of
the biosensor, we intravenously administered a known activator
of the ERK pathway, 12-O-tetradecanoylphorbol-13-acetate
(TPA), or a MEK inhibitor, PD0325901. As expected, TPA
increased the FRET/CFP ratio, whereas the MEK inhibitor
decreased it (Fig. 1c–f), indicating that EKAREV-NLS faithfully
monitors ERK activity. Thus, hereafter, we use the FRET/CFP
ratio as an index of ERK activity. In vivo time-lapse imaging then
revealed that IECs at the crypt exhibited sporadic ERK activity
pulses (Fig. 1g–j and Supplementary Movie 1). The ERK activity
pulses ﬁred spontaneously in each cell (Fig. 1g, h and Supple-
mentary Fig. 1b) or in some cases were propagated from adjacent
cells within single crypt units (Fig. 1i, j and Supplementary
Fig. 1c, d). The duration of single ERK activity pulses and the
velocity of propagation in IECs were comparable to those in
cultured cells8. These results demonstrate two modes of ERK
activity in the intestinal epithelium: the sustained, basal activity
that was evident by the decrease in ERK activity after MEK
inhibitor treatment and the pulse-like activity that may arise
spontaneously in each cell or be propagated from adjacent cells.
ERK activity dynamics in intestinal organoids. To facilitate the
analysis of ERK activity dynamics in IECs, we generated intestinal
organoids from EKAREV-NLS mice and cultured them in med-
ium containing EGF, Noggin, and R-spondin 1 (ENR medium)
(Fig. 2a, b). The growth rate and morphology of the EKAREV-
NLS organoids were indistinguishable from those of wild-type
organoids. As observed in vivo, TPA increased the FRET/CFP
ratio (Fig. 2c–e), whereas PD0325901, a potent MEK inhibitor,
decreased it (Fig. 2f–h). The FRET/CFP ratios correlated well
with the fraction of phosphorylated ERK (Supplementary Fig. 2a).
In addition, we also observed the expected effects of a BRAF
inhibitor (BRAFi) on basal ERK activity (Fig. 2i): high con-
centration of BRAFi decreased the basal ERK activity, whereas
low concentration of BRAFi contrastingly increased it, a phe-
nomenon known as paradoxical activation31. Collectively, these
results demonstrate that the EKAREV-NLS biosensor can
monitor ERK activity in intestinal organoids as sensitively as
in vivo.
We next examined whether the spatiotemporal dynamics of
ERK activity in vivo are recapitulated in intestinal organoids.
Time-lapse imaging of intestinal organoids revealed that most
cells exhibited ERK activity pulses as observed in vivo (Fig. 3a–c,
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Fig. 1 In vivo imaging of ERK activity dynamics in the mouse small intestine. a Schematic representation of the structure of the FRET biosensor for ERK
activity, EKAREV-NLS, and its mechanism of action. Upon activation, ERK phosphorylates the substrate sequence in the biosensor. The WW domain
speciﬁcally binds to the phosphorylated substrate, which brings CFP and YFP into close proximity. In this “closed” conformation state, excitation energy
absorbed by CFP is transferred to YFP without radiation, thereby enabling YFP to emit ﬂuorescence. The biosensor returns from the “closed” to the original
“open” conformation by phosphatase-dependent dephosphorylation of the substrate sequence. b Experimental setting of in vivo imaging of the small
intestine. The mouse small intestine was exteriorized, ﬁxed on the microscope stage, and observed with an inverted two-photon excitation microscope
under inhalation anaesthesia. c The representative FRET/CFP images of the small intestine of EKAREV-NLS mice before and after administration of 0.1 mg
kg−1 body weight of TPA. d Bee swarm plots showing the ERK activity (FRET/CFP ratio) in each cell before and after the TPA (n= 50 cells pooled from
three crypts). e The representative FRET/CFP images of the small intestine of EKAREV-NLS mice before and after administration of 5 mg kg−1 body
weight of a MEK inhibitor (PD0325902). f Bee swarm plots showing the FRET/CFP ratios in each cell before and after MEK inhibitor treatment (n= 50
cells pooled from three crypts). g–j In vivo time-lapse imaging of intestinal crypts of EKAREV-NLS mice. The representative images (g, i) and quantiﬁed
data from three selected cells (cells 1–3) (h, j) are shown. Note that the ERK activity pulses are spontaneously generated (g, h), or propagated from
adjacent cells (i, j). The original time course data of ERK activity used for h and j before smoothing by the moving average are shown in Supplementary
Fig. 1b, c. Scale bars, 50 µm. Red lines represent mean. Error bars represent s.e.m. Mann–Whitney U-tests were used for comparison (d, f). *P < 0.05,
**P < 0.001, ***P < 0.0001
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Supplementary Fig. 2b, c, and Supplementary Movie 2). Temporal
autocorrelation analysis of ERK activity did not show any
apparent periodicity (Fig. 3d), suggesting the stochastic nature of
the pulses. Although ERK activity pulses occurred spontaneously
in individual cells, propagation of the pulses was not observed in
intestinal organoids cultured in the ENR medium, which contains
high concentrations of EGF. Since propagation of ERK activity
was mediated by shedding of EGFR ligands in cultured cells8, 32, 33,
we reasoned that EGF supplemented in the ENR medium
decreased the sensitivity of cells to the lower amount of EGFR
ligands secreted by cells through negative-feedback mechan-
isms34–36. To test this idea, the organoids were cultured in the
absence of EGF (in the NR medium). No difference was observed
in the basal ERK activity (Fig. 3e), probably due to adaptation. As
expected, organoids cultured in NR, but not in ENR, exhibited
ERK activation upon EGF addition (Fig. 3f). Furthermore,
organoids cultured in NR occasionally exhibited cell-to-cell
propagation of ERK activity pulses (Fig. 3g, h, Supplementary
Fig. 2d, and Supplementary Movie 3). Propagation of ERK
activity pulses was diminished either by an EGFR inhibitor,
PD153035, or by a broad-spectrum matrix metalloproteinase
inhibitor, marimastat, which should suppress shedding of EGFR
ligands37, 38 (Fig. 3i, j). These results suggest that, in intestinal
organoids, propagation of ERK activity pulses requires shedding
of EGFR ligands and the resulting EGFR activation. Thus, the
ERK activity dynamics observed in the intestinal epithelium were
successfully recapitulated in intestinal organoids.
ErbB2 and EGFR generate distinct modes of ERK activity. We
next investigated the upstream signalling pathways that con-
tribute to ERK activity dynamics. Because EGFR and ErbB2 (a.k.a
human EGFR2, HER2) are often overexpressed in gastrointestinal
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Fig. 2 Characterization of mouse intestinal organoids expressing the FRET biosensor for ERK activity. a Experimental setting for live imaging of intestinal
organoids. Organoids were established from the small intestine of EKAREV-NLS mice, and cultured in media containing EGF, Noggin, and R-spondin1.
Imaging was performed within 4 days of the last passage. b A representative FRET/CFP ratio image of an EKAREV-NLS organoid cultured under normal
conditions. c–h Time-lapse imaging of ERK activity in the EKAREV-NLS organoids. Organoids were treated with 1 μM TPA (c–e) or 200 nM MEK inhibitor
(PD0325901) (f–h) at time point 0. c, f Representative time-lapse images of organoids treated with TPA (c) or a MEK inhibitor (f) are shown. d, g Time
courses of the average FRET/CFP values in the organoids (n= 90 (d) and 55 (g) cells). The FRET/CFP values in individual cells were normalized to the
mean values before the treatment. e, h Bee swarm plots of the FRET/CFP values in each cell before and after the treatment (n= 90 (e) and 66 (h) cells).
The FRET/CFP values in individual cells were normalized to the mean values before the treatment. i Time courses of the average ERK activity (FRET/CFP
ratio) in EKAREV-NLS organoids treated with 10 μM, 1 μM, or 100 nM of a BRAF inhibitor (SB590885) (n= 30, 35, and 31 cells, respectively). Scale bars,
50 µm. Red lines represent mean. Error bars represent s.e.m. Mann–Whitney U-tests were used for comparison (e, h). *P < 0.05, **P < 0.001, ***P < 0.0001
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Fig. 3 Spontaneous pulse-like ERK activation and propagation of ERK activity in intestinal organoids. a–d Time-lapse imaging of the EKAREV-NLS organoids
was performed for 90min at 1.5 min intervals (n= 71 cells). a Representative time-lapse images of ERK activity (FRET/CFP ratio) in an organoid showing
pulse-like ERK activation. b Heat map showing the time course of ERK activity (FRET/CFP ratio) in each cell. c Time courses of ERK activity in three
representative cells. The original data before smoothing by the moving average are shown in Supplementary Fig. 2c. d Temporal autocorrelation
coefﬁcients of ERK activity in the three cells shown in c. e, f Time-lapse imaging of the EKAREV-NLS organoids cultured under EGF-starved conditions for
24 h. e Bee swarm plots of ERK activity in organoids cultured under the normal condition (ENR) or EGF-starved condition (NR) (n= 193 and 148 cells
pooled from three organoids). f Time course of the average ERK activity in the control or EGF-starved organoids after stimulation with EGF. The organoids
were cultured under the normal (ENR) or EGF-starved condition (NR), and then stimulated with 50 ngml−1 of EGF at time point 0 (ENR: n= 129, NR: n=
59 cells). g Representative time-lapse images of an organoid cultured under the NR condition showing propagation of ERK activity. ERK activity (FRET/CFP
ratio) is shown in golden pseudo colour mode. h Time courses of ERK activity in the three representative cells marked in g. i, j Representative time-lapse
images of organoids treated with an EGFR inhibitor (PD153035, 1 μM) (i) or an MMP inhibitor (marimastat, 100 μM) (j). Organoids were cultured in NR
media for 24 h, and subsequently treated with either inhibitor. ERK activity is shown in the golden pseudo colour mode. Scale bars, 50 µm. Red lines
represent mean. Error bars represent s.e.m. Mann–Whitney U-test was used for comparison (e). *P < 0.05, **P < 0.001, ***P < 0.0001, n.s., not signiﬁcant
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-04527-8 ARTICLE
NATURE COMMUNICATIONS |  (2018) 9:2174 | DOI: 10.1038/s41467-018-04527-8 |www.nature.com/naturecommunications 5
cancer therapy3, 27, 39, we examined the effect of an EGFR inhi-
bitor, PD153035, and an ErbB2 inhibitor, CP-724714, on ERK
activity dynamics. Basal ERK activity was markedly decreased by
CP-724714 (ErbB2i), but not by PD153035 (EGFRi) (Fig. 4 a, b).
As expected, EGFRi but not ErbB2i abrogated EGF-induced ERK
activation (Fig. 4c), validating the speciﬁcity of the inhibitors. To
conﬁrm the effects of EGFR and ErbB2 inhibition on basal ERK
activity, dominant negative forms of EGFR (dnEGFR) and ErbB2
(dnErbB2), both of which are truncated mutants lacking their
respective intracellular domains40, 41, were introduced into the
intestinal organoids by using lentiviruses. Expression of dnErbB2,
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activity (P < 0.0001) (Fig. 4d). Moreover, knockdown of ErbB2 or
EGFR by short hairpin RNA exerted similar effects on the basal
ERK activity (Supplementary Fig. 3a, b). Taken together, these
results show that ErbB2, but not EGFR, mainly drives the basal
ERK activity in intestinal organoids.
We then examined the role of EGFR and ErbB2 in generating
the ERK activity pulses. To extract the quantitative parameters of
the pulses, time-course data of ERK activity in each cell were
ﬁtted to horizontal lines (corresponding to the sustained, constant
activity) or multi-peak functions (for the pulse-like activity). We
categorized cells exhibiting one or more ERK activity pulses, as
ERK-pulse+, or otherwise as ERK-pulse− (Supplementary
Fig. 3c–e). Treatment with EGFRi, but not that with ErbB2i,
decreased the proportion of ERK-pulse+ cells (Fig. 4e). Moreover,
the frequency of ERK activity pulses was substantially reduced by
EGFRi, but not by ErbB2i (Fig. 4f). Upon co-inhibition of EGFR
and ErbB2, the ERK activity pulses disappeared almost
completely (Fig. 4e, f). In line with this, knockdown of EGFR,
but not that of ErbB2, reduced the frequency of ERK activity
pulses (Supplementary Fig. 3f). These results show that, in
intestinal organoids, ERK activity pulses are generated by EGFR
kinase activity whereas basal ERK activity is maintained by ErbB2
kinase activity. Removal of R-spondin 1 or Noggin did not affect
basal ERK activity, its dependency on ErbB2, and the dependency
of ERK activity pulses on EGFR (Supplementary Fig. 4a–f),
negating involvement of these proteins in controlling ERK
activity dynamics in intestinal organoids. Interestingly, treatment
with a BRAF inhibitor, SB590885, not only decreased the
frequency but also prolonged the duration of ERK activity pulses
(Fig. 4g, h). As the shape of pulses generally depends on the
activity of the pulse generator, BRAF might be one of the pulse
generators in this system.
EGFR governs distinct ERK activity dynamics in adenoma
cells. The above results demonstrated distinct roles for EGFR and
ErbB2 in regulating the ERK activity dynamics in normal cells.
We next investigated how these receptors regulate ERK activity
dynamics during intestinal tumorigenesis. Organoids were
generated from adenomas developed in ApcΔ716 mice,
which have a truncation mutation in Apc42, followed by intro-
duction of the biosensor for ERK. Under our experimental con-
ditions, approximately half of the cells in the adenoma-derived
organoids expressed the biosensor (Fig. 5a). There was no sig-
niﬁcant difference in basal ERK activity between the normal and
adenoma-derived organoids (P= 0.7599) (Fig. 5a, b). However, a
striking difference was observed in the presence of EGFRi and
ErbB2i: treatment with EGFRi, which did not affect basal ERK
activity in the normal organoids (Fig. 4a, b), signiﬁcantly
decreased it in the adenoma-derived organoids (P < 0.0001)
(Fig. 5c, d). Moreover, adenoma-derived organoids were less
sensitive to ErbB2i compared to the normal organoids (Figs. 5d
and 4b). Meanwhile, EGFRi, but not ErbB2i, decreased the fre-
quency of the ERK activity pulses (Fig. 5e) and the proportion of
ERK-pulse+ cells in adenoma-derived organoids (Fig. 5f).
Treatment with both inhibitors almost completely suppressed the
ﬁring of ERK activity pulses (Fig. 5e, f). Altogether, these results
indicate that EGFR signalling is a predominant driver for basal
ERK activity and spontaneous ERK activity pulses in adenoma-
derived organoids.
Wnt signalling activation alters ERK activity dynamics.
Although deregulated/constitutive activation of Wnt signalling
caused by APC mutations is known as the initial genetic event in
the adenoma-carcinoma sequence20, accumulating evidences indi-
cate that tumour cells have already acquired epigenetic alterations
before the APC mutations43,44. Therefore, we inquired whether
activation of Wnt signalling alone could recapitulate the altered
ERK activity dynamics in adenoma-derived organoids. We utilized
a GSK3 inhibitor, CHIR99021, which causes β-catenin accumula-
tion thereby activating canonical Wnt/β-catenin signalling.
CHIR99021 did not affect the basal ERK activity at least for 24 h
(Fig. 6a, b); however, CHIR99021 surprisingly changed the cellular
responses to EGFRi and ErbB2i. In organoids treated with
CHIR99021, EGFRi decreased the basal ERK activity more potently
than did ErbB2i (Fig. 6c), as observed in the adenoma-derived
organoids. Simultaneous addition of EGFRi and ErbB2i most
strongly suppressed the basal ERK activity (Fig. 6c). The effects of
CHIR99021 disappeared after 24 h incubation in ENR medium
(without CHIR99021), suggesting that CHIR99021-induced sensi-
tivity to EGFRi was reversible (Fig. 6d). CHIR99021 also increased
the proportion of cells with ERK activity pulses (ERK-pulse+)
(Fig. 6e) and the frequency of the pulses (Fig. 6f). The ﬁring of the
ERK activity pulse was suppressed almost completely by EGFRi and
slightly by ErbB2i (Fig. 6e, f). Notably, Wnt ligand stimulation or
overexpression of constitutively active β-catenin exerted effects
similar to those of CHIR99021 on ERK activity dynamics (Sup-
plementary Fig. 5). These results suggest that activation of Wnt
signalling increases the contribution of EGFR signalling to ERK
activity thereby altering the ERK activity dynamics similar to those
in adenoma-derived organoids.
To examine the biological signiﬁcance of Wnt signalling-
dependent alterations in ERK activity dynamics, we conducted
cell cycle analyses in intestinal organoids. We generated intestinal
organoids from transgenic mice expressing a cell cycle reporter
(Fucci2a), which marks S/G2/M phase cells and G1 phase cells by
mVenus and mCherry, respectively45 (Fig. 6g). Consistent with
an essential role of ERK in cell proliferation, MEK inhibitor
treatment strongly reduced the proportion of S/G2/M phase cells
Fig. 4 EGFR and ErbB2 generate two distinct modes of ERK activity in intestinal organoids. a, b EKAREV-NLS organoids were treated with EGFRi
(PD153035) (1 μM), and/or ErbB2i (CP-724714) (10 μM), at time point 0. a Time courses of average ERK activity under each condition (EGFRi: n= 70,
ErbB2i: n= 62, EGFRi+ ErbB2i: n= 57 cells). b Quantiﬁcation of ERK activity before and after treatment with EGFRi or ErbB2i (EGFRi: n= 113, ErbB2i: n=
147 cells, pooled from two organoids). c Time course of average ERK activity in organoids that were cultured under EGF-starved condition (NR) for 24 h,
treated with either EGFRi or ErbB2i for 60min, and then stimulated with 50 ngml−1 of EGF (EGFRi: n= 48, ErbB2i: n= 32 cells). d Quantiﬁcation of ERK
activity in organoids infected with a control lentivirus (control) or lentiviruses expressing either a dominant negative form of EGFR (dnEGFR) or that of
ErbB2 (dnErbB2) (Control: n= 134, dnEGFR: n= 129, dnErbB2: n= 151 cells, pooled from ﬁve organoids cultured in the ENR medium). e, f Quantiﬁcation of
ERK activity pulses in EKAREV-NLS organoids cultured in the ENR medium and treated with EGFRi and/or ErbB2i (−/−: n= 71, EGFRi/−: n= 49,
−/ErbB2i: n= 36, EGFRi/ ErbB2i: n= 53 cells). Organoids were treated with indicated inhibitors and imaged for 90min. ERK activity data were
smoothened by 6-min moving average, and ﬁtted to ﬂat lines or multi-peak functions. e The proportion of cells exhibiting the pulse-like ERK activation
(ERK-pulse+) under each condition. f Frequencies of ERK activity pulses under each condition. Duration (g) and frequencies (h) of ERK activity pulses in
organoids cultured in the ENR medium and treated with 0, 10, 1, or 0.1 μM of a BRAF inhibitor (SB590885) for 90min (n= 55, 52, 29, and 65 cells,
respectively). Scale bars, 50 µm. Red lines represent mean. Error bars represent s.e.m. Mann–Whitney U-test (b) and Steel–Dwass test (d, f–h) were used
for comparison. *P < 0.05, ** P < 0.001, ***P < 0.0001, n.s., not signiﬁcant
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(Fig. 6h). ErbB2i, but not EGF depletion or EGFRi, signiﬁcantly
decreased the proportion of S/G2/M phase cells (P < 0.0001)
(Fig. 6h). The effect of ErbB2i was further enhanced by
simultaneous addition of EGFRi (Fig. 6h). As expected, removal
of R-spondin 1 or Noggin also decreased S/G2/M phase cells,
consistent with their roles in maintaining undifferentiated IECs
(Supplementary Fig. 6a, b). Even under the R-spondin 1- or
Noggin-depleted condition, ErbB2i reduced S/G2/M phase cells
more strongly than EGFRi (Supplementary Fig. 6a, b). These
results suggest that ErbB2 primarily drives cell cycle progression
in normal intestinal organoids and that EGFR serves as the
auxiliary driver. Thus, basal ERK activity driven by
ErbB2 signalling might play a major role in cell proliferation in
the normal organoids. Notably, treatment with CHIR99021 or
Wnt ligands, which increased the frequency of ERK activity
pulses without affecting the basal ERK activity (Fig. 6f, Supple-
mentary Fig. 5c), increased proliferating cells in an EGFR-
dependent manner (Fig. 6i, Supplementary Fig. 6c–e). Thus, the
increased frequency of ERK activity pulses correlated with
increased cell proliferation after those treatments.
GSK3 inhibitor treatment enhances EGFR signalling in vivo.
The results from intestinal organoid studies suggest the Wnt
signalling-dependent control of EGFR signalling in IECs. We thus
inquired whether administration of a GSK3 inhibitor affects
EGFR signalling in the mouse intestinal epithelium, as does it in
intestinal organoids. To this end, CHIR99021 was administered
to EKAREV-NLS mice, and ERK activity before and after
administration of a clinically used EGFR inhibitor, erlotinib was
observed. Administration of CHIR99021 increased the expression
of several genes, which were also increased by CHIR99021 in
intestinal organoids and have been reported as the Wnt-target
genes, in the intestinal epithelium (Supplementary Fig. 7a).
Intravital imaging demonstrated that erlotinib decreased the basal
ERK activity in the intestinal epithelium of CHIR99021-treated
mice but not in that of control mice (Fig. 7a). Notably,
CHIR99021 increased the expression of EGFR protein in the
crypt region that mainly comprised stem cells and progenitor
cells (Fig. 7b, c). The EGFR protein was expressed more abun-
dantly in the crypt than in the villus (Fig. 7b), where Wnt sig-
nalling activity should be low46. Moreover, EGFR expression was
markedly increased in adenomas of ApcΔ716 mice (Fig. 7d, e), as
well as adenoma-derived organoids (Fig. 7f, g) and CHIR99021-
treated organoids (Supplementary Fig. 7b, c). Thus, the increased
expression of EGFR might be involved in the Wnt signalling-
dependent augmentation of EGFR signalling. The expression
levels of ErbB2 were comparable among adenomas and the
normal epithelium (Supplementary Fig. 7d). Finally, we examined



































































































































ERK-pulse (+) ERK-pulse (–)
Fig. 5 Adenoma-derived organoids exhibit increased dependence on EGFR signalling. a, b Organoids were generated from the normal epithelium
or adenomas of the ApcΔ716 mouse small intestine, and infected with lentiviruses expressing a FRET biosensor for ERK activity (EKAREV-NLS).
a Representative images of ERK activity (FRET/CFP ratio) in organoids derived from the normal epithelium and adenomas. b Bee swarm plots of ERK
activity in the normal epithelium-derived and adenoma-derived organoids (Normal: n= 61, Adenoma: n= 99 cells, from more than three organoids).
c–f Adenoma-derived organoids expressing EKAREV-NLS were treated with 1 μM of an EGFR inhibitor (EGFRi), PD153035, and/or 10 μM of an ErbB2
inhibitor (ErbB2i), CP-724714. c Representative images of adenoma-derived organoids before and after treatment with EGFRi or ErbB2i. d Bee swarm
plots of ERK activity before and after inhibitor treatment (EGFRi: n= 120, ErbB2i: n= 119, EGFRi+ ErbB2i: n= 109 cells, pooled from three organoids).
e, f Quantiﬁcation of ERK activity pulses in adenoma-derived organoids. Organoids were treated with EGFR and/or ErbB2 inhibitors, and then imaged for
90min. ERK activity data from each cell were processed as described for Fig. 4e (−/−: n= 40, EGFRi/−: n= 45, −/ErbB2i: n= 32, EGFRi/ErbB2i: n= 29
cells). Frequencies of the pulse-like ERK activity (e) and the proportion of cells with pulse-like ERK activity (ERK-pulse+) (f) under each condition. Scale
bars, 50 µm. Red lines represent mean. Error bars represent s.e.m. Mann–Whitney U-test (b, d) and Steel–Dwass test (e) were used for comparison.
*P < 0.05, **P < 0.001, ***P < 0.0001, n.s., not signiﬁcant
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Fig. 6 Pharmacological activation of Wnt signalling promotes cell proliferation by augmenting EGFR signalling. a Representative images and b quantiﬁcation
of ERK activity in organoids treated with or without CHIR99021 (5 μM) for 24 h (n= 210 and 213 cells (from the left), from three organoids). c Time
courses of ERK activity in organoids treated with CHIR99021 for 24 h and then treated with EGFRi (PD153035), and/or ErbB2i (CP-724714) (n= 45, 29,
and 29 cells from the left). d Quantiﬁcation of ERK activity before (Pre) and after (Post) EGFRi treatment (bottom) (n= 30, 44, and 53 cells from
the left). Organoids cultured in ENR, ENR+CHIR, or ENR+CHIR99021 for 24 h and then in ENR for another 24 h (Re-ENR) were treated with EGFRi (top).
e, f Quantiﬁcation of ERK activity pulses in organoids treated with CHIR99021 for 24 h and then with EGFRi and/or ErbB2i for 90min during imaging. The
proportion of cells with ERK activity pulses (ERK-pulse+) (e), and the frequency of the pulses (f) under each condition (n= 36, 47, 47, and 25 cells from
the left). g Schematic structure of Fucci2a (top), cell cycle diagram marked with corresponding ﬂuorescence (bottom left), and the representative image of
organoid expressing Fucci2a (bottom right). h, i Proportion of cells in the S/G2/M phases in the Fucci2a organoids. h Organoids were cultured for 24 h in
ENR, EGF-deﬁcient medium (NR), or ENR supplemented with EGFRi ErbB2i, and/or a MEK inhibitor (MEKi) (n= 158, 264, 400, 359, 423, and 243 cells
(from the left), from more than four organoids). i Organoids treated with CHIR99021 for 24 h were subsequently treated with EGFRi, and/or ErbB2i
for another 24 h (n= 156, 1062, 461, 220, and 234 cells (from the left), from more than four organoids). Scale bars, 50 µm. Red lines represent mean.
Error bars represent s.e.m. Mann–Whitney U-test (b, d), Steel–Dwass test (f), and χ2 test with BH procedure (h, i) were used for comparison.*P < 0.05,
**P < 0.001, ***P < 0.0001, n.s., not signiﬁcant
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-04527-8 ARTICLE
NATURE COMMUNICATIONS |  (2018) 9:2174 | DOI: 10.1038/s41467-018-04527-8 |www.nature.com/naturecommunications 9
proliferation and survival in the intestinal epithelium. We found
that administration of CHIR99021 promoted proliferation of crypt
cells, whereas erlotinib did not exhibit a signiﬁcant effect (Fig. 7h,
i, Supplementary Fig. 7e, f). Remarkably, simultaneous adminis-
tration of CHIR99021 and erlotinib strongly suppressed the pro-
liferation of crypt cells (Fig. 7h, i, Supplementary Fig. 7e, f),
promoted apoptosis (Supplementary Fig. 7g), and severely dis-
turbed the crypt–villus structures (Fig. 7h). These results suggest
that in vivo administration of CHIR99021 enhances EGFR
signalling and promotes proliferation and survival of IECs, and
that enhancement of EGFR signalling renders cells highly sensitive
to EGFR inhibition in vivo. It is also noteworthy that autopho-
sphorylation of ErbB2 was suppressed by ErbB2i, but not by
EGFRi, in normal and adenoma organoids (Supplementary
Fig. 8a–d). Thus, EGFR might be dispensable for ErbB2 activation.
Wnt signalling controls ERK activity via EGFR regulators.
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expression changes regulate EGFR–ERK signalling dynamics. For
this purpose, we analyzed gene expression proﬁles of normal
(ENR) and CHIR99021-treated organoids (ENR+ CHIR) by
using microarrays. We identiﬁed 81 and 274 transcripts whose
expression levels were upregulated and downregulated, respec-
tively, in CHIR99021-treated organoids by more than 3 folds
(Fig. 8a, Supplementary Data 1). Gene set enrichment analysis
revealed that CHIR99021 induced gene expression changes
similar to those in the Apc-knockout epithelium and colorectal
adenomas (Fig. 8b–e). Indeed, gene sets comprising genes
downregulated and upregulated after Apc knockout were most
signiﬁcantly enriched in the CHIR99021-dependent down-
regulated and upregulated gene list, respectively (Supplementary
Table 1). Notably, CHIR99021 altered the expression of four
genes whose protein products promote (Egﬂ6, Flna, and Troy) or
suppress (Lrig3) EGFR signalling47–50 (Supplementary Data 1).
The expression levels of Dusps, Sprys, Spreds, and MIG6, which
also regulate EGFR–ERK signalling35, were not signiﬁcantly
altered by CHIR99021 (Supplementary Fig. 9a). RT-PCR analyses
conﬁrmed that Egﬂ6, Flna, and Troy were upregulated, and that
Lrig3 was downregulated in CHIR99021-treated organoids
(Fig. 8f) and adenoma-derived organoids (Fig. 8g). To examine
whether these genes mediate the altered ERK activity dynamics in
adenomas, we performed exogenous expression and knockdown
of these genes in adenoma-derived organoids (Supplementary
Fig. 9b). The knockdown of Egﬂ6 or expression of Lrig3 abolished
the sensitivity of adenoma cells to EGFR inhibition (Fig. 8h).
Meanwhile, the frequency of ERK activity pulses was signiﬁcantly
decreased by the Lrig3 expression (P= 0.0001) and the Troy
knockdown (P= 0.0009) in adenoma organoids (Fig. 8i).
Knockdown of Flna did not signiﬁcantly affect ERK activity
dynamics in either experiment (Fig. 8h, i). These results suggest
that decreased expression of Lrig3 and increased expression of
Egﬂ6 and Troy, probably together with enhanced EGFR
expression, coordinately promotes EGFR–ERK signalling in
adenoma cells.
Discussion
The spatiotemporal regulation of ERK signalling has been con-
sidered a key determinant of cellular responses in many biological
contexts51, 52, and its disturbance has been implicated in many
diseases including cancers2. Here, we successfully visualized ERK
activity in the intestinal epithelium and unveiled the roles of
EGFR and ErbB2 in regulating ERK activity dynamics. We found
that EGFR kinase activity is required for ERK activity pulses, and
that ErbB2 is the primary tyrosine kinase governing basal ERK
activity and cell proliferation in intestinal organoids (Figs. 4
and 6). ERK activity in IECs comprises the ErbB2-dependent
constant component and EGFR-dependent pulse-like component
(Fig. 8j). Remarkably, Wnt signalling activation, which often
occurs during intestinal tumorigenesis, enhanced EGFR–ERK
signalling, at least in part, by controlling expression of EGFR and
its regulators, such as Egﬂ6, Lrig3, and Troy (Figs. 7 and 8). This
alteration increased the contribution of EGFR to the basal ERK
activity, increased the frequency of ERK activity pulses, and
promoted proliferation of IECs (Figs. 6 and 7). Thus, Wnt sig-
nalling activation sensitized IECs to pharmacological inhibition of
EGFR signalling (Fig. 7). These results show that distinct
upstream tyrosine kinase receptors can generate different modes
of ERK activity dynamics to control cellular responses, and that
deregulation of such mechanisms might underlie the character-
istic features of cancer cells.
Upon Wnt signalling activation, augmented EGFR signalling
increased the frequency of ERK activity pulses, which was cor-
related with the increased proliferation of IEC (Figs. 6 and 7).
Importantly, however, these results do not indicate that the
pulsatile nature of EGFR–ERK signalling per se is needed for the
promotion of cell proliferation. Notably, ErbB2 inhibition
decreased the basal ERK activity less efﬁciently in adenomas or in
GSK3 inhibitor-treated organoids than in normal organoids
(Figs. 5 and 6). This shows that, after Wnt signalling activation,
basal ERK activity is maintained at a constant level through
adaptation to enhanced EGFR signalling, which increases the
relative contribution of EGFR to the ERK activity.
We demonstrated that EGFR, but not ErbB2, is a major gen-
erator of the ERK activity pulses (Fig. 4e, f). The distinct con-
tribution of EGFR and ErbB2 to ERK activity dynamics might be
attributed to the different regulatory mechanisms involved. Since
EGFR–ERK signalling activity can be affected by the ﬂuctuation
of the topical concentration of EGFR ligands and also be regu-
lated by multiple negative feedback mechanisms35, 36, 53, these
effects might introduce a pulsatile nature into EGFR signalling. In
contrast to EGFR, ErbB2 does not have any known ligands and its
activity is mainly regulated by dimerization54. In addition, ErbB2-
containing heterodimers, compared to dimers without ErbB2,
exhibit slower rates of endocytosis and dissociation from
ligands55–57. Considering all these studies, the ErbB2 homodimer
and ErbB2-containing heterodimers might be more stable and
transmit sustained, constant inputs to ERK. Importantly,
knockdown of EGFR did not affect basal ERK activity (Supple-
mentary Fig. 3b), which is dependent on ErbB2 kinase activity.
Moreover, an ErbB2 inhibitor, but not an EGFR inhibitor,
reduced autophosphorylation of ErbB2 (Supplementary
Fig. 8a–d), suggesting that the majority of ErbB2 autopho-
sphorylation is mediated by ErbB2, but not by EGFR. Thus,
ErbB2 seems to be activated mainly via homodimerization,
Fig. 7 EGFR signalling is augmented in adenomas and CHIR99021-treated mouse intestine in vivo. a Bee swarm plots of ERK activity in the vehicle-
(Control) or CHIR99021-treated (CHIR) mouse intestinal epithelium before (Pre) and after (Post) treatment with an EGFR inhibitor, erlotinib. Mice were
injected with vehicle or 20mg kg−1 body weight of CHIR99021 for 3 days and then treated with 100mg kg−1 body weight erlotinib for 30min (Control: n=
48, CHIR: n= 61 cells from three crypts). b, c Immunoﬂuorescence staining of the small intestine in the mice injected with vehicle (Control) or CHIR99021
for 3 days using anti-EGFR and anti-E-cadherin antibodies. b The ratio of EGFR and E-cadherin staining intensities is shown in the IMD mode according to
the colour scale. Counterstaining was performed with Hoechst. Note that strong staining of stromal cells results from non-speciﬁc binding of the secondary
antibodies used here (anti-mouse IgG). c Quantiﬁcation of the EGFR/E-cadherin staining intensity ratio in each cell under vehicle or CHIR99021-treated
condition (n= 50 cells). d Immunoﬂuorescence staining of an adenoma and the normal small intestine of ApcΔ716 mice with anti-EGFR and anti-E-cadherin
antibodies. EGFR/E-cadherin staining intensity ratio is shown in the IMD mode. e Quantiﬁcation of the EGFR/E-cadherin ratio in each cell located in the
indicated regions (n= 50 cells). f Immunoﬂuorescence staining of normal and adenoma-derived organoids with anti-EGFR and anti-ErbB2 antibodies.
EGFR/ErbB2 staining intensity ratio is shown in the IMD mode. g Quantiﬁcation of the EGFR/ErbB2 ratio in each cell in the organoids (n= 40 cells pooled
from at least two organoids). h, i EdU staining of the small intestine of CHIR99021- and/or erlotinib-treated mice. Mice were injected with vehicle, 20mg
kg−1 body weight of CHIR99021, and/or 100mg kg−1 body weight of erlotinib for 3 days. i Quantiﬁcation of EdU+ cells per crypt section (−/−: n= 46,
CHIR/–: n= 42, −/Erlotinib: n= 54, and CHIR/Erlotinib: n= 45 crypts from three mice). Scale bars, 50 µm. Red lines represent mean. Error bars represent
s.e.m. Mann–Whitney U-test (a, c, g), and Steel–Dwass test (e, i) were used for comparison.*P < 0.05, **P < 0.001, ***P < 0.0001
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although our data could not rule out the involvement of EGFR
and ErbB3 in the ErbB2 activation. In any case, our results
indicate that the upstream receptors under the control of different
regulatory mechanisms can generate distinct modes of ERK
activity dynamics. Consistently, distinct mechanisms acting at the
receptor level are involved in different ERK activity dynamics in
cultured mammary epithelial cells58. Since our results also suggest
the involvement of Raf in generating ERK activity pulses (Fig. 4g,
h), multiple feedback loops might govern the pulses at different
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has a kinase activity-independent function as a heterodimeriza-
tion partner of ErbB2. However, our results did not support the
contribution of EGFR to ErbB2 activation, as discussed above.
Thus, the observed functions of EGFR are likely to be mediated
by intracellular signalling triggered by EGFR kinase activity,
which is referred to as EGFR signalling in this study.
Different dynamics of receptor tyrosine kinases could lead to
distinct dynamics of the downstream ERK activity35. For exam-
ple, in PC12 cells, activated EGFR rapidly undergoes the clathrin-
based endocytosis and the following degradation, whereas acti-
vation of TrkA, a receptor for NGF, induces its translocation to
long-lived signalling endosomes, where TrkA avoids degradation
and mediates sustained ERK activation59. Thus, mechanisms
regulating dynamics of speciﬁc receptors can regulate ERK
activity dynamics. In this study, we identiﬁed Egﬂ6, Lrig3, and
Troy as important regulators of EGFR–ERK signalling dynamics
in IECs (Fig. 8). Previously, these proteins have been reported to
regulate EGFR signalling in cultured cells47–49. Notably, altered
expression of these regulators was associated with changes in ERK
activity dynamics in adenoma cells (Fig. 8). Thus, elucidation of
mechanisms by which these regulators function in IECs would
provide a clue about how ERK activity dynamics can be altered
during tumorigenesis and how it affects tumour cell phenotypes.
EGFR signalling has been implicated in many cancers and its
pharmacological inhibition has been considered promising for
cancer treatment4, 5. Our results might provide a therapeutic
rationale for why EGFR inhibitors can speciﬁcally suppress the
growth of certain types of CRCs without severe adverse effects.
Since strong activation of Wnt signalling augments EGFR sig-
nalling and renders cells highly dependent on EGFR signalling
(Figs. 6 and 7), it can be readily speculated that pharmacological
inhibition of EGFR preferentially targets CRCs rather than nor-
mal IECs harbouring weaker Wnt signalling activity. Con-
sistently, administration of a GSK3 inhibitor (CHIR99021), which
promoted expression of, at least a fraction of, Wnt-target genes,
increased the sensitivity of normal IECs to EGFR inhibition
in vivo (Fig. 7). Importantly, however, the effects of CHIR99021
administration and Wnt signalling activation are not completely
the same, as many events other than GSK3β inhibition occur in
Wnt signalling and GSK3 plays various roles independently of
Wnt signalling. Also, the effects of CHIR99021 were not as strong
as those of Wnt signalling activation; CHIR99021 promoted cell
proliferation only weakly whereas genetic activation of Wnt sig-
nalling has been shown to cause hyperplasia in the intestinal
epithelium. Nevertheless, CHIR99021 exerted similar effects on
ERK activity dynamics and expression of several genes both
in vitro and in vivo. In addition to EGFR signalling, our results
also demonstrate the signiﬁcant contribution of ErbB2 signalling
to ERK activity in IECs. Indeed, proliferation of IECs was more
effectively suppressed by concomitant inhibition of EGFR and
ErbB2compared to inhibition of either one. Consistent with this
ﬁnding, simultaneous inhibition of EGFR and ErbB2 has been
shown to be effective in refractory CRCs60, though inhibition of
ErbB2 alone was ineffective. Thus, our ﬁndings and the proposed
model are in good agreement with the clinical efﬁcacy of EGFR
and ErbB2 inhibition in CRC treatment. Nevertheless, it should
be noted that there are signiﬁcant differences between mouse
adenomas and human CRCs. In particular, mouse adenomas are
usually assumed to have only Apc mutations, whereas human
CRCs often contain many genetic mutations, which might affect
cellular responses to EGFR inhibition. Indeed, CRCs harbouring
RAS or RAF mutations are resistant to EGFR inhibitors, and
initially sensitive CRCs can also acquire the resistance via several
mechanisms28.
Recent studies have shown that ErbB signalling regulates the
transition between quiescence and proliferation of ISCs18, 19. For
instance, a pan-ErbB negative regulator, Lrig1, is expressed in a
quiescent, long-lived subpopulation of ISCs, which is distinct
from the Lgr5+ population and serves as an origin of intestinal
tumours18, 19, 61. Lrig1 depletion increases the expression of ErbB
family receptors and enhances ERK activity, resulting in ISC
expansion and adenoma formation18, 19. Thus, Lrig1 plays a
crucial role in controlling quiescence and proliferation of ISCs. In
this study, we showed that Wnt signalling activation, increases
the expression of EGFR, but not ErbB2 (Fig. 7). Since Lrig1
broadly regulates the expression of ErbB receptors18, 19, selective
induction of EGFR suggests Lrig1-independent regulation of
EGFR expression. More recently, Basak and colleagues have
reported that EGFR–ERK signalling mediates ISC proliferation
and that inhibition of EGFR and ErbB2, MEK, or ERK induces
reversible quiescence of ISCs62. Notably, they also showed that
inhibition of EGFR alone could suppress proliferation of ISCs62.
In contrast, we did not observe any signiﬁcant alterations in cell
proliferation after EGFR inhibition for 24 h. This discrepancy
could be due to the difference in experimental settings, since they
mainly focused on the effects of long-term perturbation on ISC
functions62 whereas we focused on the immediate effects of the
treatment, which more likely reﬂect alterations in rapidly cycling
progenitors rather than in ISCs. Since stem cells harbour strong
Wnt signalling activity46, inhibition of EGFR alone might sup-
press their proliferation in the long term.
In conclusion, we have revealed ERK activity dynamics regu-
lated by two distinct upstream receptors, EGFR and ErbB2, in the
intestinal epithelium and shown that alterations in the dynamics
caused by Wnt signalling activation underlie the high sensitivity
of tumour cells to EGFR inhibition. These ﬁndings highlight the
importance of understanding ERK activity dynamics and their
role in controlling cellular functions at the single cell level, issues
that could not be addressed by conventional biochemical
approaches. Similar phenomena could have occurred for many
Fig. 8 Wnt signalling activation affects EGFR–ERK signalling dynamics through regulating expression of multiple molecules. a A volcano plot depicting the
fold changes in gene expression levels between normal (ENR) and CHIR99021-treated organoids (ENR+ CHIR), and statistical signiﬁcance of the changes.
b–e Enrichment plots from gene set enrichment analysis (GSEA). GESA plots for genes downregulated after Apc knockout (b), genes upregulated after Apc
knockout through Myc (c), genes downregulated in colorectal adenoma (d), and genes upregulated in colorectal adenoma (e) are shown. f, g RT-PCR
analysis revealed that Egﬂ6, Flna, and Troy were upregulated, and that Lrig3 was downregulated in both CHIR99021-treated and adenoma-derived
organoids. The relative mRNA levels of indicated genes in normal (ENR) versus CHIR99021-treated organoids (ENR+ CHIR) (f), and those in normal
versus adenoma-derived organoids (g) are shown (n= 3 samples containing more than ten organoids). h, i Adenoma-derived organoids expressing the
ERK biosensor were infected with lentiviruses expressing control vector (control), Lrig3 (Lrig3), or shRNAs for Egﬂ6 (shEgﬂ6), Flna (shFlna), or Troy
(shTroy). h Bee swarm plots of ERK activity in organoids before (Pre) and after (Post) EGFR inhibitor treatment under each condition (n= 80 cells pooled
from two organoids). i The frequency of ERK activity pulses under each condition. Time-lapse imaging was performed for 90min (n= 50 cells). j
Schematic representation of ERK activity dynamics generated by kinase activity of EGFR and ErbB2 in the normal and Wnt signalling-activated intestinal
epithelia. Red lines represent mean. Error bars represent s.e.m. Welch’s t test (f, g), Mann–Whitney U-test (h), and Steel–Dwass test (i) were used for
comparison.*P < 0.05, **P < 0.001, ***P < 0.0001
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other signalling pathways and molecules, elucidation of which
should be an important future research area to improve the
understanding of cellular drug responses at the single cell level.
Live imaging with highly sensitive FRET biosensors could be a
powerful tool to address these issues and shed new light on the
mechanisms involved in many physiological and pathological
processes.
Methods
Lentivirus production and infection of intestinal organoids. The FRET bio-
sensor for ERK has been described previously7. The dominant negative form of
EGFR (dnEGFR) is a C-terminally truncated mutant encoding amino acid 1 to
67940, and the dominant negative form of ErbB2 (dnErbB2) encodes 1 to 693,
respectively41. Both were generated by PCR using mouse cDNA encoding the
corresponding full-length protein as the template. Lentivirus expressing a con-
stitutively active form of β-catenin was described previously63. Constructs
expressing shRNAs were made by inserting corresponding oligonucleotides into a
CSII-U6-MCS-puro vector64. The target sequences of shRNAs are shown in Sup-
plementary Table 2. The FRET biosensor was cloned into pCSIIbsr, and dominant
negative constructs were cloned into pCSIIpuro, both of which are derived from
pCSII-EF (a gift from Hiroyuki Miyoshi)65, to produce lentiviruses. For virus
production, Lenti-X 293T cells (Clontech) were transfected with the pCSII plas-
mids, together with psPAX2 and pCMV-VSV-G-RSV-Rev plasmids. The culture
supernatants containing the lentiviruses were collected 48 h after transfection, ﬁl-
tered, concentrated with the Lenti-X concentrator (Clontech), and then used to
infect intestinal organoids.
Mice. Transgenic mice expressing the FRET biosensor for ERK (EKAREV mice)
have been described previously30. FRET mice were backcrossed to C57BL/6N Jcl
(CLEA Japan) for more than ten generations. To date, no disease or anomaly has
been observed in these mice. Fucci2a mice were provided by the RIKEN BRC
through the National Bio-Resource Project of the MEXT, Japan45. ApcΔ716 mice
have been reported previously42. Mice were housed in a speciﬁc pathogen-free
facility and provided with a standard diet and water ad libitum. In some experi-
ments, CHIR99021 (20 mg kg−1 body weight, Cayman Chemical), erlotinib (100
mg kg−1 body weight, Wako Pure Chemical Industries), and/or vehicle (dimethyl
sulfoxide, DMSO) were intraperitoneally injected daily to 7-week-old C57BL/6
mice for 3 days. No statistical method was used to predetermine sample size. The
experiments were not randomized. The investigators were not blinded to allocation
during experiments and outcome assessment. The animal protocols were reviewed
and approved by the Animal Care and Use Committee of Kyoto University
Graduate School of Medicine (No. 10584).
Microscopy. For two-photon excitation microscopy (2PM), we used an
FV1200MPE-IX83 inverted microscope (Olympus) equipped with a 30×/1.05 NA
silicon oil-immersion objective lens (UPLSAPO 30XS; Olympus), an LCV110-MPE
incubator microscope (Olympus) equipped with a 25×/1.05 water-immersion
objective lens (XLPLN 25XWMP2; Olympus), and an InSight DeepSee Laser
(Spectra Physics). The laser power was set to 3–18%. The scan speed was set
between 4–12.5 μs per pixel. Z-stack images were acquired at 1–10 μm intervals. In
time-lapse analyses, images were recorded every 1–3 min. The excitation wave-
length for CFP was 840 nm. We used an IR-cut ﬁlter (BA685RIF-3), two dichroic
mirrors (DM505 and DM570), and two emission ﬁlters (BA460-500 for CFP and
BA520-560 for YFP) (Olympus). Confocal images were acquired with an FV1000/
IX83 confocal microscope (Olympus) equipped with a 30×/1.05 NA silicon oil-
immersion objective lens (UPLSAPO 30XS; Olympus).
In vivo observation of the small intestine. Intravital imaging of the small
intestine was performed as described previously66. Mice were anaesthetized with
1.5–2% isoﬂurane (Abbott) inhalation and placed in the supine position on an
electric heating pad maintained at 37 °C. Before surgery, the abdominal area of the
mouse was disinfected using 70% ethanol. A small vertical incision was made on
the right side of the abdominal wall. The small intestine was pulled out of the
abdominal cavity, and both proximal and distal sides of the small intestine of
interest were ligated using 5-0 surgical silk sutures (Nesco Suture). After PBS was
administered into the intestinal cavity with a 29-gauge needle, the small intestine
was put on a cover glass placed on a heat-stage maintained at 37 °C, and ﬁxed with
surgical sutures to minimize peristalsis. No drugs were used to stop peristalsis of
the intestinal tract. Instead, we dilated the small intestine by injecting PBS into the
cavity in order to minimize the peristalsis. Time-lapse imaging was then performed
with an FV1200MPE-IX83 two-photon excitation microscope under control of the
FluoView software (Olympus). In some experiments, 0.1 mg kg−1 body weight of
TPA (LC laboratories) or 5 mg kg−1 body weight of PD0325901 (EMD Millipore)
was administered via the caudal vein, and 100 mg kg−1 body weight of erlotinib
(Wako Pure Chemical Industries) was injected intraperitoneally during imaging.
Mice were euthanized after the experiments.
Intestinal organoid culture. Small intestinal organoids were generated according
to the published protocol29. Brieﬂy, intestinal crypts were isolated from the mouse
small intestine by incubation for 30 min at 4 °C in PBS containing 2 mM EDTA,
and cultured in Advanced DMEM/F12 Medium (Thermo Fisher Scientiﬁc) sup-
plemented with EGF (50 ng ml−1, PeproTech), Noggin (100 ng ml−1, PeproTech),
and R-spondin1 (500 ng ml−1, R&D Systems). Adenoma cells were isolated from
the ApcΔ716 mouse small intestinal adenomas by incubation for 60 min at 4 °C in
PBS containing 2 mM EDTA. Organoids were embedded in Growth Factor
Reduced Matrigel (Corning), and maintained by serial passaging. Organoids were
imaged using an incubator-type two-photon excitation microscope, LCV110-MPE,
within 4 days of the last passage in order to minimize the autoﬂuorescence emitted
from the cell debris accumulating in their central cavities. In some experiments,
organoids were treated with TPA (1 μM, LC laboratories), PD0325901 (200 nM,
Calbiochem), PD153035 (1 μM, MedChemexpress), CP-724714 (10 μM, AdooQ),
Marimastat (100 μM, R&D Systems), or SB590885 (100 nM–10 μM, LKT Labora-
tories). For EGF starvation, organoids were cultured in media without EGF for 24
h. For pharmacological activation of Wnt signalling, organoids were cultured in
media supplemented with CHIR99021 (5 μM, Cayman Chemical) for 24 h. For
Wnt ligand stimulation, organoids were cultured in media supplemented with
mouse recombinant Wnt3a (100 ng ml−1, R&D Systems). We generated organoids
expressing the dominant negative form of either EGFR or ErbB2 and adenoma-
derived organoids expressing EKAREV using the aforementioned lentiviruses as
described previously67. All organoids were generated from mice housed in a spe-
ciﬁc pathogen-free facility, and assumed to be free from mycoplasma
contamination.
Image processing. Acquired images were analyzed with MetaMorph software
(Universal Imaging) as described previously30,68. Brieﬂy, FRET efﬁciency was
visualized as FRET/CFP ratio images shown in the intensity-modulated display
mode, in which eight colours from red to blue represent the FRET/CFP ratio and
the 32 grades of colour intensity represent the ﬂuorescence intensity of CFP
according to the colour scale shown in each ﬁgure. In order to analyze the Z-stack
images, we performed maximum intensity projection, in which voxels with the
maximum intensity at each x–y coordinate were projected in the visualization
plane. To reduce the noise of in vivo imaging data, a 5 × 5 median ﬁlter was applied
to the FRET/CFP ratio images. In addition, time course data of the FRET/CFP
values in each cell were smoothened by 6-min moving averages. Quantitative
parameters of pulsatile ERK activation were obtained as follows. First, FRET/CFP
values in each cell were calculated for all time frames. Second, the FRET/CFP
values were smoothened by 6-min moving averages. Subsequently, the smoothed
time series for each cell was ﬁtted to either a ﬂat line or a multi-peak function:
y tð Þ ¼ ω0 ðN ¼ 0Þ
max y1 tð Þ; ¼ ; yN tð Þf g þ ω0 ðN  1Þ

;
where N and wo indicate the number of ERK activity pulses and basal ERK activity,
respectively, max() is a function returning the maximum value of input variables
and yi(t) indicates time-course of the ith ERK activity pulse represented by
yi tð Þ ¼ Aiφi t  tið Þ;
where Aiand ti are the amplitude and timing of the ith ERK pulse, respectively, and
φi sð Þ is a radial basis function. We here adopted a cosine function within a single
period, i.e., φi(s)=cos(ωis)+ 1 if π=ωi  s  π=ωi or φi(s)= 0 otherwise. Para-
meters (Ai, ti, and wi) were optimized by minimizing the square error between a
ﬁtting function and the observed ERK activity. If one of the amplitudes Ai was
greater than threshold, cells whose data were ﬁtted to the multi-peak function were
deﬁned as “ERK-pulse+”, otherwise they were deﬁned as “ERK-pulse−”. The data
analysis was performed with MATLAB software (MathWorks).
Immunoﬂuorescence staining. Small intestine specimens were washed with cold
PBS, and ﬁxed overnight in 10% formalin in PBS at 4 °C. The tissues were
sequentially treated with PBS containing 12, 15, and 18% sucrose (for more than 2
h for each treatment), embedded in O.C.T. compound (Tissue-Teck), frozen, and
sectioned at 8-μm thickness. Sections were subjected to immunoﬂuorescence
staining with the following primary antibodies: anti-EGFR (Medical & Biological
Laboratories, clone 6F1), anti-ErbB2 (Cell Signaling Technology, clone 29D8), anti-
phospho-ErbB2 (Cell Signaling Technology, clone 6B12), anit-Ki67 (Abcam,
ab15580), and anti-E-cadherin (Cell Signaling Technology, clone 24E10). The
sections were treated with 0.5% Triton X-100 in TBS for 10 min. Antigen retrieval
was performed by treating samples for 20 min in Tris-EDTA buffer, pH 8.0. Alexa
Fluor 488 conjugated goat anti-rabbit IgG (Molecular Probes, no. A-11008), Alexa
Fluor 546 conjugated goat anti-rabbit IgG (Molecular Probes, no. A-11035), or
Alexa Fluor 488 conjugated goat anti-mouse IgG (Molecular Probes, no. A-11029;
dilution: 1:500) were used as secondary antibodies. Counterstaining was performed
with Hoechst 33342 (Molecular Probes, no. H3570). For EdU staining, mice were
injected intraperitoneally with EdU (80 μg g−1 body weight) 2 h before euthani-
zation. Organoids were treated with 10 μM of EdU for 2 h before staining. EdU
staining was performed using the Click-iT EdU Alexa Fluor 488 Imaging Kit (Life
Technologies, no. C10337), according to the manufacturer’s instructions.
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Extraction of RNA and qRT-PCR. IECs were isolated by incubating and shaking
intestinal specimens in cold PBS containing 5 mM EDTA. Total RNA was
extracted from the isolated IECs or intestinal organoids by using an RNeasy Mini
Kit (QIAGEN). The extracted total RNA was reverse-transcribed into cDNA by
using a High-Capacity cDNA Reverse Transcription Kit (Thermo Fisher Scientiﬁc).
Quantitative PCR analyses were performed by using an Applied Biosystems Ste-
pOne Real-Time PCR System and Power SYBR Green PCR Master Mix (Thermo
Fisher Scientiﬁc). The expression data were normalized to those of GAPDH or
β-actin.
Microarray analysis. For microarray analysis, we performed two independent
series of experiments. Total RNA was extracted from intestinal organoids cultured
in the ENR media supplemented with or without CHIR99021 (5 μM) for 4 days as
described above. Synthesis of cDNA, in vitro transcription and labelling of cRNA,
and hybridization to the Mouse Gene 1.0 ST arrays (Affymetrix, Santa Clara, CA,
USA) were performed according to the manufacturer's protocols. The CEL ﬁles
were analyzed by Transcriptome Analysis Console (TAC) 4.0 software (Thermo
Fisher Scientiﬁc). Expression signals of all genes (probe sets) were calculated using
the RMA algorithm. Gene set enrichment analysis was performed by using GSEA
3.0 software (Broad Institute)69.
Statistical analysis. Mann–Whitney U-test was performed to analyze the statis-
tical difference between two sets of data. Welch’s t test was performed when the
number of samples was less than 6. As a multiple comparison test, the Steel–Dwass
test was used after validation of homoscedasticity by the Bartlett’s test. BH pro-
cedure was used for adjustment for multiple comparisons in χ2 test. P values less
than 0.05 were considered statistically signiﬁcant. No statistical method was used to
predetermine sample size. All statistical analyses were performed using the JMP
Pro 13 software and R software (ver. 3.4.1).
Data availability. The data that support the ﬁndings of this study are available
within the article and its Supplementary Information or from the corresponding
author upon reasonable request. The microarray data have been deposited in the
Gene Expression Omnibus (GEO) database under the accession code GSE110257
(https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE110257).
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